Skip to main content
Top
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | Joint Infection | Research

The burden of skin and soft tissue, bone and joint infections in an Australian cohort of people who inject drugs

Authors: B. Morgan, R. Lancaster, B. Boyagoda, R. Ananda, LO Attwood, D. Jacka, I. Woolley

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Introduction

There are currently limited data regarding the clinical and economic significance of skin and soft tissue infections (SSTI) and bone and joint infections in Australian people who inject drugs (PWID).

Methods

Retrospective cohort study in adult PWID admitted to Monash Health, a large heath care network with six hospitals in Victoria, Australia. Inpatients were identified using administrative datasets and International Classification of Disease (ICD-10) coding for specific infection-related conditions. Cost analysis was based on mean ward, intensive care and hospital-in-the-home (HITH) lengths of stay. Spinal infections and endocarditis were excluded as part of previous studies.

Results

A total of 185 PWID (61 female, 124 male, median age 37) meeting the study criteria were admitted to Monash Health between January 2010 and January 2021. Admitting diagnoses included 78 skin abscesses, 80 cellulitis, 17 septic arthritis, 4 osteomyelitis, 3 thrombophlebitis and 1 each of necrotising fasciitis, vasculitis and myositis. Pain (87.5%) and swelling (75.1%) were the most common presenting complaints. Opioids (67.4%) and methamphetamine (37.5%) were the most common primary drugs injected. Almost half (46.5%) of patients had concurrent active hepatitis C (HCV) infection on admission. Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV) were uncommon. The most significant causative organism was methicillin-susceptible Staphylococcus aureus (24.9%). In 40.0% (74/185) no organism was identified. Patients required a median acute hospital stay of 5 days (2–51 days). There were 15 patients admitted to the intensive care unit (ICU) with median duration 2 days. PICC line insertion for antibiotics was required in 16.8% of patients, while 51.4% required surgical intervention. Median duration of both oral and IV antibiotic therapy was 11 days. Almost half (48.6%) of patients were enrolled in an opioid maintenance program on discharge. Average estimated expenditure was AUD $16, 528 per admission.

Conclusion

Skin and soft tissue and joint infections are a major cause of morbidity for PWID. Admission to hospital provides opportunistic involvement of addiction specialty services.
Appendix
Available only for authorised users
Literature
1.
go back to reference Larney S, Hickman M, Guy R, Grebely J, Dore GJ, Gray RT, et al. Estimating the number of people who inject drugs in Australia. BMC Public Health. 2017;17(1):1–7.CrossRef Larney S, Hickman M, Guy R, Grebely J, Dore GJ, Gray RT, et al. Estimating the number of people who inject drugs in Australia. BMC Public Health. 2017;17(1):1–7.CrossRef
2.
go back to reference Sutherland RU, King J, Jones C, Karlsson F, Gibbs A, Price D, Raimondo O, Dietze B, Lenton P, Salom S, Daly C, Thomas C, Juckel N, Agramunt J, Wilson S, Que Noy Y, Wilson W, Degenhardt J, Farrel L, Peacock M. A. Australian drug Trends 2022: key findings from the national illicit drug reporting system (IDRS) interviews. Australian Institute of Health and Welfare; 2022. Sutherland RU, King J, Jones C, Karlsson F, Gibbs A, Price D, Raimondo O, Dietze B, Lenton P, Salom S, Daly C, Thomas C, Juckel N, Agramunt J, Wilson S, Que Noy Y, Wilson W, Degenhardt J, Farrel L, Peacock M. A. Australian drug Trends 2022: key findings from the national illicit drug reporting system (IDRS) interviews. Australian Institute of Health and Welfare; 2022.
3.
go back to reference Nambiar D, Stoové M, Hickman M, Dietze P. A prospective cohort study of hospital separations among people who inject drugs in Australia: 2008–2013. BMJ open. 2017;7(8):e014854.CrossRefPubMedPubMedCentral Nambiar D, Stoové M, Hickman M, Dietze P. A prospective cohort study of hospital separations among people who inject drugs in Australia: 2008–2013. BMJ open. 2017;7(8):e014854.CrossRefPubMedPubMedCentral
4.
go back to reference Chambers H. Skin and Soft Tissue Infections in persons who inject drugs. Infect Dis Clin N Am. 2021;35(1):169–81.CrossRef Chambers H. Skin and Soft Tissue Infections in persons who inject drugs. Infect Dis Clin N Am. 2021;35(1):169–81.CrossRef
5.
go back to reference Collier MG, Doshani M, Asher A. Using Population based Hospitalization Data to Monitor increases in conditions causing morbidity among persons who inject drugs. J Community Health. 2018;43(3):598–603.CrossRefPubMed Collier MG, Doshani M, Asher A. Using Population based Hospitalization Data to Monitor increases in conditions causing morbidity among persons who inject drugs. J Community Health. 2018;43(3):598–603.CrossRefPubMed
6.
go back to reference Baltes A, Akhtar W, Birstler J, Olson-Streed H, Eagen K, Seal D, et al. Predictors of skin and soft tissue infections among sample of rural residents who inject drugs. Harm Reduct J. 2020;17(1):1–10.CrossRef Baltes A, Akhtar W, Birstler J, Olson-Streed H, Eagen K, Seal D, et al. Predictors of skin and soft tissue infections among sample of rural residents who inject drugs. Harm Reduct J. 2020;17(1):1–10.CrossRef
7.
go back to reference Dunleavy K, Munro A, Roy K, Hutchinson S, Palmateer N, Knox T, et al. Association between harm reduction intervention uptake and skin and soft tissue infections among people who inject drugs. Drug Alcohol Depend. 2017;174:91–7.CrossRefPubMed Dunleavy K, Munro A, Roy K, Hutchinson S, Palmateer N, Knox T, et al. Association between harm reduction intervention uptake and skin and soft tissue infections among people who inject drugs. Drug Alcohol Depend. 2017;174:91–7.CrossRefPubMed
8.
go back to reference Marks LR, Munigala S, Warren DK, Liang SY, Schwarz ES, Durkin MJ. Addiction medicine consultations reduce readmission rates for patients with serious infections from opioid use disorder. Clin Infect Dis. 2019;68(11):1935–7.CrossRefPubMed Marks LR, Munigala S, Warren DK, Liang SY, Schwarz ES, Durkin MJ. Addiction medicine consultations reduce readmission rates for patients with serious infections from opioid use disorder. Clin Infect Dis. 2019;68(11):1935–7.CrossRefPubMed
9.
go back to reference Ananda RA, Attwood LO, Lancaster R, Jacka D, Jhoomun T, Danks A et al. The clinical and financial burden of spinal infections in people who inject drugs. Intern Med J. 2021. Ananda RA, Attwood LO, Lancaster R, Jacka D, Jhoomun T, Danks A et al. The clinical and financial burden of spinal infections in people who inject drugs. Intern Med J. 2021.
10.
go back to reference Low ZM, Krishnaswamy S, Woolley IJ, Stuart RL, Boers A, Barton TL, et al. Burden of infective endocarditis in an Australian cohort of people who inject drugs. Intern Med J. 2020;50(10):1240–6.CrossRefPubMed Low ZM, Krishnaswamy S, Woolley IJ, Stuart RL, Boers A, Barton TL, et al. Burden of infective endocarditis in an Australian cohort of people who inject drugs. Intern Med J. 2020;50(10):1240–6.CrossRefPubMed
11.
go back to reference Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.CrossRefPubMed Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.CrossRefPubMed
12.
go back to reference R Development Core Team. R: a languange and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021. R Development Core Team. R: a languange and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021.
13.
go back to reference Binswanger IA, Takahashi TA, Bradley K, Dellit TH, Benton KL, Merrill JO. Drug users seeking emergency care for soft tissue infection at high risk for subsequent hospitalization and death. J Stud Alcohol Drug. 2008;69(6):924–32.CrossRef Binswanger IA, Takahashi TA, Bradley K, Dellit TH, Benton KL, Merrill JO. Drug users seeking emergency care for soft tissue infection at high risk for subsequent hospitalization and death. J Stud Alcohol Drug. 2008;69(6):924–32.CrossRef
15.
go back to reference Summanen PH, Talan DA, Strong C, McTeague M, Bennion R, Thompson JE Jr., et al. Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of Intravenous Drug Use. Clin Infect Dis. 1995;20(Supplement2):279–S82.CrossRef Summanen PH, Talan DA, Strong C, McTeague M, Bennion R, Thompson JE Jr., et al. Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of Intravenous Drug Use. Clin Infect Dis. 1995;20(Supplement2):279–S82.CrossRef
16.
go back to reference AURA. 2021: Fourth Australian report on antimicrobial use and resistance in human health. Australian Commision on Safety and Quality in Health Care; 2021. AURA. 2021: Fourth Australian report on antimicrobial use and resistance in human health. Australian Commision on Safety and Quality in Health Care; 2021.
17.
go back to reference Kelly MC, Yeager SD, Shorman MA, Wright LR, Veve MP. Incidence and predictors of Gram-negative Bacilli in hospitalized people who inject drugs with Injection Drug Use-Attributable infections. Antimicrob Agents Chemother. 2021;65(12):e00925–21.CrossRefPubMedPubMedCentral Kelly MC, Yeager SD, Shorman MA, Wright LR, Veve MP. Incidence and predictors of Gram-negative Bacilli in hospitalized people who inject drugs with Injection Drug Use-Attributable infections. Antimicrob Agents Chemother. 2021;65(12):e00925–21.CrossRefPubMedPubMedCentral
19.
go back to reference Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10–e52.CrossRefPubMed Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10–e52.CrossRefPubMed
21.
go back to reference Ebright JR, Pieper B. Skin and soft tissue infections in injection drug users. Infect Disease Clin. 2002;16(3):697–712. Ebright JR, Pieper B. Skin and soft tissue infections in injection drug users. Infect Disease Clin. 2002;16(3):697–712.
22.
go back to reference Murphy EL, DeVita D, Liu H, Vittinghoff E, Leung P, Ciccarone DH, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis. 2001;33(1):35–40.CrossRefPubMed Murphy EL, DeVita D, Liu H, Vittinghoff E, Leung P, Ciccarone DH, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis. 2001;33(1):35–40.CrossRefPubMed
23.
go back to reference Harris RE, Richardson J, Frasso R, Anderson ED. Experiences with skin and soft tissue infections among people who inject drugs in Philadelphia: a qualitative study. Drug Alcohol Depend. 2018;187:8–12.CrossRefPubMed Harris RE, Richardson J, Frasso R, Anderson ED. Experiences with skin and soft tissue infections among people who inject drugs in Philadelphia: a qualitative study. Drug Alcohol Depend. 2018;187:8–12.CrossRefPubMed
24.
go back to reference Attwood LO, McKechnie M, Vujovic O, Higgs P, Lloyd-Jones M, Doyle JS, et al. Review of management priorities for invasive infections in people who inject drugs: highlighting the need for patient‐centred multidisciplinary care. Med J Australia. 2022;217(2):102–9.CrossRefPubMed Attwood LO, McKechnie M, Vujovic O, Higgs P, Lloyd-Jones M, Doyle JS, et al. Review of management priorities for invasive infections in people who inject drugs: highlighting the need for patient‐centred multidisciplinary care. Med J Australia. 2022;217(2):102–9.CrossRefPubMed
25.
go back to reference Ti L, Ti L. Leaving the hospital against medical advice among people who use illicit drugs: a systematic review. Am J Public Health. 2015;105(12):e53–e9.CrossRefPubMedPubMedCentral Ti L, Ti L. Leaving the hospital against medical advice among people who use illicit drugs: a systematic review. Am J Public Health. 2015;105(12):e53–e9.CrossRefPubMedPubMedCentral
26.
go back to reference Suzuki J, Johnson J, Montgomery M, Hayden M, Price C, editors. Outpatient parenteral antimicrobial therapy among people who inject drugs: a review of the literature. Open forum infectious diseases. Oxford University Press US; 2018. Suzuki J, Johnson J, Montgomery M, Hayden M, Price C, editors. Outpatient parenteral antimicrobial therapy among people who inject drugs: a review of the literature. Open forum infectious diseases. Oxford University Press US; 2018.
27.
28.
go back to reference Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018;113(3):545–63.CrossRefPubMed Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018;113(3):545–63.CrossRefPubMed
29.
go back to reference Naji L, Dennis B, Rosic T, Wiercioch W, Paul J, Worster A et al. Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: a systematic review and meta-analysis. Drug Alcohol Depend. 2022:109295. Naji L, Dennis B, Rosic T, Wiercioch W, Paul J, Worster A et al. Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: a systematic review and meta-analysis. Drug Alcohol Depend. 2022:109295.
30.
go back to reference Ronsley C, Nolan S, Knight R, Hayashi K, Klimas J, Walley A, et al. Treatment of stimulant use disorder: a systematic review of reviews. PLoS ONE. 2020;15(6):e0234809.CrossRefPubMedPubMedCentral Ronsley C, Nolan S, Knight R, Hayashi K, Klimas J, Walley A, et al. Treatment of stimulant use disorder: a systematic review of reviews. PLoS ONE. 2020;15(6):e0234809.CrossRefPubMedPubMedCentral
31.
go back to reference Weinstein ZM, Wakeman SE, Nolan S. Inpatient addiction consult service: expertise for hospitalized patients with complex addiction problems. Med Clin. 2018;102(4):587–601. Weinstein ZM, Wakeman SE, Nolan S. Inpatient addiction consult service: expertise for hospitalized patients with complex addiction problems. Med Clin. 2018;102(4):587–601.
32.
go back to reference Colledge-Frisby S, Curtis SJ, Dietze PM, Doyle JS, Hickman M, Higgs P, et al. Prevalence and incidence of emergency department presentations and hospital separations with injecting-related infections in a longitudinal cohort of people who inject drugs. Epidemiol Infect. 2023;151:e192.CrossRefPubMedPubMedCentral Colledge-Frisby S, Curtis SJ, Dietze PM, Doyle JS, Hickman M, Higgs P, et al. Prevalence and incidence of emergency department presentations and hospital separations with injecting-related infections in a longitudinal cohort of people who inject drugs. Epidemiol Infect. 2023;151:e192.CrossRefPubMedPubMedCentral
Metadata
Title
The burden of skin and soft tissue, bone and joint infections in an Australian cohort of people who inject drugs
Authors
B. Morgan
R. Lancaster
B. Boyagoda
R. Ananda
LO Attwood
D. Jacka
I. Woolley
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09143-0

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.